PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study.

Shohei Tobu, Hirokazu Takahashi, Hiroshi Isoda, Kenji Fujimoto, Mitsuru Noguchi

Abstract read

In one paragraph

Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shohei TobuDepartment of Urology, Faculty of Medicine, Saga University, Nabeshima, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan. toubu7@cc.saga-u.ac.jp.ORCID https://orcid.org/0000-0002-8266-6652

Hirokazu TakahashiDivision of Metabolism and Endocrinology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan.

Hiroshi IsodaLiver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan.

Kenji FujimotoOccupational Health Data Science Centre, Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishiku, Kitakyushu, 807-8555, Japan.

Mitsuru NoguchiDepartment of Urology, Faculty of Medicine, Saga University, Nabeshima, 5-1-1 Nabeshima, Saga City, Saga, 849-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate whether regular prostate-specific antigen (PSA) testing is associated with the receipt of curative treatment for prostate cancer among men in Japan and to identify associated factors.

methodsA retrospective analysis was conducted using the claims data from the National Health Insurance and Late-Stage Elderly Health Care System in Saga Prefecture between March 2014 and March 2022. Patients were categorized into PSA testing (≥ 1 test ≥ 6 months before treatment) and non-PSA testing groups. Curative treatment was defined as either a radical prostatectomy or carbon-ion radiotherapy. Multivariable logistic regression was used to identify the factors associated with curative treatment.

resultsAmong 2,200 patients, 737 (33.5%) underwent PSA testing, and 708 (32.2%) received curative treatment. Patients who underwent PSA testing were older and more likely to participate in Specific Health Checkups. The proportion receiving curative treatment was higher in the PSA testing group (36.4% vs. 30.1%, p < 0.001). Age (OR = 0.85), PSA testing (OR = 1.53), and participation in Specific Health Checkups, which do not include PSA testing, were independently associated with curative treatment (OR = 1.64).

conclusionsPSA testing was associated with a higher likelihood of receiving curative treatment for prostate cancer. Participation in Specific Health Checkups may reflect a population more engaged in preventive healthcare or with greater access to screening opportunities.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsAgedAged, 80 and overEarly Detection of CancerEast Asian PeopleHumansJapanMaleProstatectomyRetrospective StudiesProstate-Specific AntigenCurative treatmentElderlyPopulation-based studyProstate cancerProstate-specific antigenPSA testing

Identifiers

PMID42919289

DOI10.1186/s12894-026-02266-3

PMCPMC13688820

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.